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ransformation of ﬁbroblasts by oncogenic Src causes
disruption of actin stress ﬁbers and formation of inva-
sive adhesions called podosomes. Because the small
GTPase Rho stimulates stress ﬁber formation, Rho inactivation
by Src has been thought to be necessary for stress ﬁber
disruption. However, we show here that Rho[GTP] levels
do not decrease after transformation by activated Src. Inac-
tivation of Rho in Src-transformed ﬁbroblasts by dominant
negative RhoA or the Rho-speciﬁc inhibitor C3 exoenzyme
disrupted podosome structure as judged by localization of
T
 
podosome components F-actin, cortactin, and Fish. Inhibition
of Rho strongly inhibited Src-induced proteolytic degra-
dation of the extracellular matrix. Furthermore, development
of an in situ Rho[GTP] afﬁnity assay allowed us to detect
endogenous Rho[GTP] at podosomes, where it colocalized
with F-actin, cortactin, and Fish. Therefore, Rho is not
globally inactivated in Src-transformed ﬁbroblasts, but is
necessary for the assembly and function of structures impli-
cated in tumor cell invasion.
 
Introduction
 
Regulation of actin dynamics, cell-substrate adhesion, and
ECM remodeling is key to the invasive capacity of onco-
genically transformed cells. Transformation of fibroblasts
in culture by activated mutants of Src, either v-Src or c-Src
(Y527F), provides a well-characterized model system for
study of regulatory mechanisms involved in tumorigenesis.
Oncogenic Src regulates actin bundling and capping pro-
teins and focal adhesion proteins, affects integrin function,
and promotes expression and secretion of matrix metallo-
proteinases (Frame, 2004). Active Src also promotes the for-
mation of podosomes (Tarone et al., 1985), specialized
structures at the cell-substrate interface similar to the invasive
structures found in macrophages and osteoclasts (for review
see Linder and Aepfelbacher, 2003). Podosomes contain a
complex array of actin and adhesion regulatory proteins
including F-actin, Src, FAK, PI(3)-kinase, integrins, cortactin,
vinculin, N-WASP, p190RhoGAP, and Fish (Abram et al.,
2003; Linder and Aepfelbacher, 2003). Membrane-bound
and secreted matrix metalloproteinases are also localized to
podosomes, resulting in concentration of extracellular proteo-
lytic activity at these sites. Individual podosomes often accu-
mulate in ring-like structures termed rosettes (Chen, 1989).
The Rho family GTPases RhoA and Cdc42, well-known
for controlling actin dynamics (Hall, 1998), have been impli-
cated in podosome formation in osteoclasts and endothelial
cells, respectively (Chellaiah et al., 2000b; Moreau et al.,
2003). Rho activity is regulated upon adhesion to ECM pro-
teins (Ren et al., 1999), a process under the control of Src
family kinases (Klinghoffer et al., 1999). In addition, Rho
GTPases are regulated during polarized movement of fibro-
blasts controlled by Src (Timpson et al., 2001). The original
observation that oncogenic Src causes actin stress fiber loss
has lead to the widely held hypothesis that Rho or Rho-
dependent signaling is inhibited in transformed cells (Frame
et al., 2002). This hypothesis has been supported by the
observations that overexpression of constitutively active mutants
of Rho can cause restoration of actin stress fibers in Src-
transformed fibroblasts (Fincham et al., 1996; Mayer et al.,
1999). However, here we show that endogenous Rho is not
inactivated in Src-transformed cells. Instead, active Rho is
necessary for Src-induced podosome assembly and function.
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Inhibition of Rho by either expression of dominant negative
RhoA or treatment with C3 exoenzyme perturbs both podo-
some structure and function. Rho inhibition leads to disrup-
tion of F-actin, and disruption of cortactin and Fish localiza-
tion at podosomes, accompanied by a dramatic decrease in
protease secretion as measured by in situ zymography. We
developed a high resolution in situ Rho[GTP] affinity assay,
which revealed that Rho[GTP] is enriched in podosomes,
where it colocalizes with F-actin, cortactin and Fish. These
findings suggest dynamic regulation of Rho in Src-trans-
formed fibroblasts.
 
Results and discussion
 
To directly test the hypothesis that Rho is inactivated in fi-
broblasts transformed by oncogenic Src, we used a Rho af-
finity precipitation assay, which takes advantage of the selec-
tive interaction of the Rho binding domain (RBD) of the
effector rhotekin with active Rho[GTP] (Ren et al., 1999).
As expected, GST-RBD selectively precipitated transfected
constitutively active Rho, but not dominant negative Rho,
as well as endogenous Rho[GTP] from Swiss3T3 cells stim-
ulated with serum (unpublished data). The rhotekin RBD
binds both RhoA and the highly related family member
RhoC (Reid et al., 1996). With commercial antibodies, we
have not observed a difference between the family members
in biochemical assays, so we refer to both activities collec-
tively as Rho.
We detected no decrease in Rho[GTP] levels in v-Src-
transformed NIH3T3 cells compared with nontransformed
control cells growing in the presence of serum under either
sub-confluent or confluent conditions (Fig. 1 A), in agree-
ment with a previous report on Src-transformed rat cells
(Pawlak and Helfman, 2002). Similarly, there was no differ-
ence in endogenous Rho[GTP] levels in NIH3T3 cells
transformed with oncogenic c-Src(Y527F) relative to control
cells (Fig. 1 B). Activation of temperature-sensitive v-Src (ts-
v-Src) did not cause a decrease in Rho[GTP] (Fig. 1 C, lanes
1–7), though Src kinase activity was induced within 1 h (un-
published data). Instead, 6 h after activation of ts-v-Src we
observed a modest but reproducible activation of Rho (Fig.
1 C, lanes 8–9).
Our observation that endogenous Rho[GTP] levels are
not reduced in Src-transformed cells prompted us to exam-
ine whether Rho function might be required for some aspect
of oncogenic transformation. To test this hypothesis, we
transiently transfected dominant negative RhoA(S19N) into
NIH3T3 cells expressing c-Src(Y527F). Staining for F-actin
revealed that dominant negative Rho had striking effects on
the actin cytoskeleton (Fig. 2, C and G). Transfected cells
generally became flattened and more spread, and the cell
shape changes were accompanied by an overall loss of actin
polymerization. The effect on the actin cytoskeleton was
most pronounced at the podosome rosettes, which appeared
to be totally or partially disorganized. Expression of domi-
nant negative RhoA(S19N) had a similar effect on polymer-
ized actin in several different clones of NIH3T3 fibroblasts
expressing v-Src, although in those cells podosomes appear
as small dot-like structures instead of rosettes (unpublished
data). Transient overexpression of RhoA(Q63L) either caused
stress fiber formation in some cells, as reported previously
(Fincham et al., 1996; Mayer et al., 1999), or in the major-
ity of cells induced extreme cell rounding accompanied by a
cortical ring of actin (unpublished data).
To exclude the possibility that overexpression of RhoA
(S19N) exerts nonspecific effects on other Rho-related
GTPases, we used recombinant Tat-C3 exoenzyme (Sahai
and Marshall, 2003) to inhibit Rho. Tat-C3 enters cells via
receptor-mediated endocytosis and specifically ADP-ribo-
sylates and inhibits Rho (Sekine et al., 1989). Endogenous
Rho was efficiently modified by the inhibitor, because all of
the detectable Rho underwent a mobility shift in polyacryl-
amide gels (unpublished data). In most of the Src-trans-
formed cells, Tat-C3 exerted similar effects to those exerted
by dominant negative Rho. The cells flattened dramatically
and had irregular plasma membrane extensions (Fig. 2, com-
pare A with B and compare E with F). In addition, actin
polymerization was disrupted at rosettes in c-Src(Y527F)
cells (Fig. 2, B and F) and at individual podosomes in v-Src
cells (unpublished data). Inhibition of Rho in Src-trans-
formed cells did not cause apoptosis, as judged by DAPI
staining (Fig. 2, I–K).
Because RhoA has been implicated in podosome forma-
tion in osteoclasts (Chellaiah et al., 2000b) and dendritic
cells (Burns et al., 2001), we further investigated the effect of
Rho inhibition on podosome integrity by immunostaining
Figure 1. Endogenous Rho is active in cells expressing oncogenic 
Src. (A–C) Rho affinity pull-down assays were used to determine the 
level of active Rho. In each panel, an anti-RhoA/B/C antibody was 
used to visualize Rho[GTP] in pellet fractions (top blot) or total Rho 
in 5% of the cell lysate (bottom blot). (A) Rho activity in duplicate 
samples of control (vector, lanes 1, 2, 5, and 6) and v-Src–transformed 
(lanes 3, 4, 7, and 8) NIH3T3 fibroblasts growing in 10% FCS under 
subconfluent (lanes 1–4) or confluent conditions (lanes 5–8). 
(B) Rho[GTP] levels in duplicate lysates from NIH3T3 fibroblasts 
expressing empty vector (lanes 1–2) or c-Src(Y527F) (lanes 3–4). 
(C) Rho pull-down assays of lysates from subconfluent cultures of 
NIH3T3 cells expressing ts-v-Src(tsLA90). Cells were serum-starved 
for 20 h at 39.5 C (lanes 1–8) or at 37 C (lane 9) and then shifted 
to 37 C for the indicated times. 
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for two different podosome components: the Src substrates
cortactin (Okamura and Resh, 1995) and Fish (Abram et al.,
2003). Consistent with the loss of polymerized actin, we did
not detect cortactin or Fish at podosome rosettes after treat-
ment of Src(Y527F) cells with Tat-C3 (Fig. 3, compare A
with C and compare B with D). Similarly, expression of
dominant negative Rho disrupted cortactin localization to
rosettes in Src(Y527F) cells (Fig. 3 E).
Matrix proteases are localized to podosomes and rosettes
(Linder and Aepfelbacher, 2003). MMP-2 secretion in fi-
broblasts transformed by v-Src is dependent on a v-Src-
FAK-JNK pathway (Hauck et al., 2002). Interestingly,
RhoA- and JNK-dependent pathways reportedly interact to
influence MMP-9 secretion in keratinocytes (Turchi et al.,
2003). To investigate the functional significance of podo-
some loss after Rho inhibition, we asked whether Rho func-
tion is necessary for Src-induced ECM degradation. Src-
transformed fibroblasts were cultured on cross-linked gelatin
conjugated to a fluorescent dye, and protease secretion was
indicated by formation of small nonfluorescent patches be-
neath the cells (Fig. 4, A and D). As expected, these patches
very often colocalized with F-actin (Fig. 4, G–I). Treatment
of Src(Y527F)-expressing cells with Tat-C3 almost com-
pletely abolished protease secretion compared with un-
treated cells (Fig. 4, A, B, and J). In contrast, pharmacologi-
cal inhibition of the Rho effector Rho-kinase with Y-27632
did not significantly affect gelatin degradation (Fig. 4, C and
J), suggesting that the effect of Rho on podosomes is not
mediated by the Rho-kinase pathway. Interestingly, Sahai
and Marshall (2003) have recently demonstrated that a
“blebbing” mode of tumor cell invasion requires the Rho–
ROCK pathway but not pericellular proteolysis, suggesting
Rho can regulate cell invasion by different mechanisms in
different cellular contexts. We also found that expression of
constitutively active RhoA(Q63L) inhibited Src-induced
gelatin degradation (Fig. S1, G–J, available at http://www.
jcb.org/cgi/content/full/jcb.200312168/DC1), but to a
lesser extent than dominant negative RhoA(S19N) (Fig. S1,
A, D, and J). It is possible that the effects of RhoA(Q63L)
Figure 2. Inhibition of Rho disrupts F-actin in 
Src-transformed fibroblasts. Src(Y527F) fibroblasts 
exponentially growing on glass were left untreated 
(A, E, and I) or treated with 0.5  M Tat-C3 for 18 h 
(B, F, and J) and processed for immunofluorescence. 
Another set of Src(Y527F) fibroblasts were trans-
fected with myc-RhoA(S19N) for 24 h, and plated 
on glass for an additional 12 h (C, D, G, H, and K) 
before processing for immunofluorescence. (A–C) 
F-actin staining at low magnification. (D) myc 
costaining corresponding to field in C. Arrows in C 
and D indicate transfected cell. (E–H) High magni-
fication images of representative cells from the 
same experiments. (E–G) F-actin; (H) myc. G and 
H correspond to the same cell. (I–K) DAPI staining 
of corresponding nuclei in E–G. Bars: (D) 30  m; 
(H) 9.5  m.
 
Figure 3.
 
Inhibition of Rho in Src-transformed fibroblasts causes 
podosome disassembly.
 
 Mouse fibroblasts expressing Src(Y527F) 
exponentially growing on glass were left untreated (A and B) 
or treated with 0.5 
 
 
 
M Tat-C3 for 18 h (C and D). Another set 
of Src(Y527F) fibroblasts were transfected with myc-RhoA(S19N) for 
24 h, and plated on glass for an additional 12 h (E). Samples were 
processed for immunostaining for cortactin (A, C, and E) or Fish 
(B and D). Arrowheads in A and B indicate podosome rosettes. Inset 
in E shows myc costaining of the cell in E (arrows). Bar, 17.5 
 
 
 
m. 
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may be due, at least in part, to the rounding that occurs in
the majority of the transfected cells and the consequent de-
crease in cell-substratum contact area. However, these find-
ings suggest that cycling of Rho between GTP-bound and
GDP-bound states may be important for matrix degradation
induced by oncogenic Src.
Localization of the Src substrate and Rho regulator
p190RhoGAP to invadopodia in metastatic melanoma cells
(Nakahara et al., 1998) and to podosomes in Src-transformed
cells (Gavazzi et al., 1989) raises the possibility of spatially re-
stricted regulation of Rho at those sites. Therefore, we devel-
oped an in situ Rho[GTP] affinity assay to determine the sub-
cellular distribution of endogenous active Rho. Fixed cells
were incubated with purified soluble GST-RBD, and specific
binding was detected by anti-GST staining. While this manu-
script was in preparation, a similar assay was described (Du-
breuil et al., 2003). As in the affinity precipitation assay, con-
stitutively active RhoA(Q63L) was strongly recognized by
soluble GST-RBD (Fig. S2, B and E, available at http://
www.jcb.org/cgi/content/full/jcb.200312168/DC1). Soluble
GST-RBD-AAA (see Online supplemental material), which
contains point mutations that diminish binding to Rho[GTP]
(Fig. S2 A and Fig. S3 A, available at http://www.jcb.org/cgi/
content/full/jcb.200312168/DC1), recognized overexpressed
RhoA(Q63L) to a much lesser extent, and GST alone yielded
an almost undetectable signal (Fig. S2, compare B–D), con-
firming the specificity of the assay.
We were also able to use soluble GST-RBD to detect en-
dogenous Rho[GTP] in Src-transformed fibroblasts (Fig.
S3, B and E). As with transfected mutants of Rho, endoge-
nous Rho[GTP] was specifically detected by wild-type GST-
RBD. In matched controls, the mutant GST-RBD-AAA
showed reduced binding, and GST alone yielded negligible
staining (Fig. S3, B–D). Rho[GTP] appeared at various ven-
tral adhesions and membrane ruffles in nontransformed fi-
broblasts (unpublished data). Strikingly, with this assay we
observed an enrichment of Rho[GTP] at podosome rosettes
in cells expressing Src(Y527F) (Fig. 5, A, D, and G), where
it colocalized with cortactin (Fig. 5, B and C), Fish (Fig. 5, E
and F), and actin (Fig. 5, H and I). High magnification im-
ages show that Rho[GTP] is concentrated at individual
podosomes in a pattern similar to that of F-actin (Fig. S3,
compare E with F). As a further confirmation of the specific-
ity of the in situ affinity assay for Rho[GTP], no localized
Rho[GTP] was detectable after Tat-C3 treatment, even at
sites where residual F-actin was still detectable at partially
disrupted podosome rosettes (Fig. 5, J–L). These data dem-
onstrate for the first time that endogenous active Rho is con-
centrated at sites of actin remodeling and ECM invasion in
oncogenically transformed cells.
Podosomes are dynamic structures that are continually as-
sembled and rearranged on time scales of the order of min-
utes. Our finding that Rho[GTP] is concentrated in podo-
somes (Fig. 5) raises the possibility that Rho activation
occurs at these sites. FRET-based analysis of Rac activation
has revealed that membrane recruitment of Rac1 and release
of RhoGDI are restricted spatially to sites of integrin en-
gagement (Del Pozo et al., 2002). It is conceivable that Rho
is activated in an analogous manner because podosomes con-
tain numerous proteins, including FAK, that could activate
or recruit Rho-specific guanine nucleotide exchange factors
(Hauck et al., 2002; Zhai et al., 2003). In addition, Src
Figure 4. Inhibition of Rho but not ROCK impairs 
Src-induced protease secretion. Src(Y527F) cells 
exponentially growing on plastic in complete 
medium were treated with vehicle (A and D), 0.5 
 M Tat-C3 (B and E), or 10  M Y-27632 (C and F) 
for 20 h. Cells were then trypsinized and plated on 
glass coverslips coated with cross-linked Oregon 
green
®–labeled gelatin in medium containing the 
indicated inhibitor. After 3 h, cells were fixed and 
stained for F-actin and DAPI. (A–C) Superimposed 
images of gelatin (green) and DAPI (blue). (D–F) 
Superimposed images of the same fields in A–C 
corresponding to F-actin (red) and DAPI (blue). 
(G–I) High magnification images of untreated con-
trol samples in the same experiment. Degradation 
patches in Oregon green
®–labeled gelatin (G, ar-
rows) and F-actin condensation at podosomes (H, 
arrows) colocalize when red and green channels are 
merged (I, arrows). (J) Gelatin degradation was 
quantified and is represented as the percent of cells 
able to form degradation patches (see Materials 
and methods). Results are the mean ± SD of three 
different experiments. Bars: (F) 32  m; (I) 6  m. 
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could activate an exchange factor directly by tyrosine phos-
phorylation (Chikumi et al., 2002). Based on our in situ
Rho[GTP] assay in fixed cells, we cannot determine whether
Rho is activated at podosomes or activated elsewhere and
subsequently recruited. p190RhoGAP phosphorylation by
v-Src strongly correlates with the onset of morphological
transformation (Fincham et al., 1999). Given the reported
localization of p190RhoGAP to invasive structures and our
observation that both constitutively active and dominant
negative RhoA inhibit podosome function (Fig. S1), it is
tempting to speculate that active Src stimulates both GTP
hydrolysis and GDP-GTP exchange on Rho at podosomes.
Rho[GTP] might stimulate podosome formation through
phosphatidylinositol-4-phosphate 5-kinase-dependent pro-
duction of PIP
 
2
 
 (Chong et al., 1994), which activates the ac-
tin capping and severing protein gelsolin, an obligate podo-
some component in osteoclasts (Chellaiah et al., 2000a).
Additionally, through its effector mDia1, Rho[GTP] coor-
dinates microtubules, which are important for podosome
regulation in macrophages (Linder et al., 2000). Alterna-
tively, it is possible that Rho-dependent actin polymeriza-
tion is required to maintain localization of activated Src to
podosomes, as is the case for trafficking of ts-v-Src to focal
adhesions before their degradation (Fincham et al., 1996).
Thus, Rho function may be necessary for localization of Src
to podosomes, regulation of actin dynamics within podo-
somes, or both.
We have shown that Rho is not inactivated by oncogenic
Src, that Rho function is specifically required for podosome
integrity and function, and that endogenous Rho[GTP] is
localized to podosome rosettes in Src-transformed cells. Src
kinase activity is elevated in many types of human cancers
(Frame, 2004), and elevated expression of RhoA and RhoC
has been correlated with increased metastatic potential in
numerous human tumor cells (Sahai and Marshall, 2002). It
will be interesting to determine whether the invasive capac-
ity of tumor cells with elevated Src activity results from Rho-
dependent protease secretion.
 
Materials and methods
 
In situ zymography
 
Glass coverslips were prepared essentially as described previously (Muel-
ler et al., 1992). In brief, they were coated with Oregon green
 
®
 
 488-conju-
gated gelatin (0.2 mg/ml in 2% sucrose buffer), cross-linked 15 min in
0.5% glutaraldehyde in PBS, and incubated for 3 min with 5 mg/ ml
NaBH
 
4
 
 in PBS. After quenching with DME at 37
 
 
 
C, cells were plated on
Figure 5. Active Rho[GTP] at podosome rosettes 
colocalizes with podosome components. Src(Y527F) 
cells exponentially growing on glass were left 
untreated (A–I) or were treated with 0.5  M Tat-C3 
for 18 h (J–L). After fixation, cells were incubated 
with 50  g/ml of soluble GST-RBD. Rho[GTP]-
bound RBD was detected by GST immunostaining 
(A, D, G, and J, green). The same samples were 
costained for the podosome components cortactin 
(B), Fish (E), or F-actin (H, control; K, Tat-C3), red. 
Merged green (Rho[GTP]) and red (podosome 
component) channels are shown in C, F, I, and L 
(yellow). Arrows in A–I indicate rosettes; arrow-
heads in J–L indicate disrupted rosettes. Bar, 14  m. 
322 The Journal of Cell Biology 
 
|
 
 
 
Volume 166, Number 3, 2004
coated coverslips in DME containing 10% FCS with or without inhibitors
and incubated at 37
 
 
 
C for 3 or 4 h before processing for immunostaining.
Results were quantified by counting cells degrading matrix, as defined by
ability to form at least one degradation patch regardless of its size, and rep-
resented as a percentage of the total (50 cells per treatment in at least two
independent experiments).
 
In situ Rho[GTP] affinity assay
 
In situ detection of active Rho was conceptually based on a similar assay
developed for detecting Ras[GTP] (Sherman et al., 2000), but adapted for
Rho[GTP] and optimized to allow subcellular resolution. Cells growing on
glass coverslips were briefly washed in PBS and immediately fixed with
freshly prepared 4% PFA in PBS for 10 min RT. After a 30-min incubation
in PBS containing 3% BSA, 0.1 M glycine, and 0.05% Triton X-100 fol-
lowed by 15 min in the same buffer containing 15% goat serum, samples
were washed three times in ice-cold wash buffer (0.5% BSA, 0.1 M glycine
in PBS) and incubated with the indicated concentrations of soluble GST-
RBD, GST-RBD-AAA, or GST for 2 h at 4
 
 
 
C. Samples were washed three
times and incubated in wash buffer containing 15% goat serum for 30 min
followed by incubation with either monoclonal (1:800) or polyclonal anti-
GST (1:500) in wash buffer containing 5% goat serum for 1 h at RT. For
costaining, samples were incubated with both primary antibodies over-
night at 4
 
 
 
C. Signal was detected by incubation with biotin anti–mouse or
anti–rabbit IgG (1:200) for 45 min RT followed by a 30-min incubation
with streptavidin Alexa Fluor
 
®
 
 488 with or without rhodamine-phalloidin
to detect F-actin (1:100). Samples were mounted in SlowFade
 
®
 
 antifade re-
agent containing DAPI. (See Online supplemental material for further de-
tails.) Images were obtained with a Zeiss510 LSM.
 
Online supplemental material 
 
The Materials and methods section contains additional details including
the origin and production of stable cell lines, sources of antibodies and re-
agents, generation of DNA constructs, methods of biochemical analyses
(GTPase pull-down assays, purification of recombinant proteins), and con-
ditions used for immunocytochemistry and imaging. 
Fig. S1 shows that dominant negative Rho, and to a lesser extent consti-
tutively active Rho, both inhibit gelatin degradation by Src-transformed fi-
broblasts. Fig. S2 shows that recombinant GST-RBD specifically recog-
nizes constitutively active Rho(Q63L) in vitro and in situ, whereas mutant
GST-RBD-AAA has reduced affinity for constitutively active Rho in vitro
and in situ. Fig. S3 further demonstrates the specificity of GST-RBD for en-
dogenous active Rho in vitro and in situ. Online supplemental material is
available at http://www.jcb.org/cgi/content/full/jcb.200312168/DC1.
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